E-MP's copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :		(11) International Publication Number:
A61K 38/18, C12N 15/12, 15/62	A1	WO 95/28949
		(43) International Publication Date: 2 November 1995 (02.11.95)

(21) International Application Number: PCT/DK95/00121

(22) International Filing Date: 17 March 1995 (17.03.95)

(30) Priority Data:

0464/94	21 April 1994 (21.04.94)	DK
1452/94	21 December 1994 (21.12.94)	DK

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(71) Applicant *(for all designated States except US)*: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: FLODGAARD, Hans, Jakob, Hem [DK/DK]; Melvillevej 6, DK-2900 Hellerup (DK). RASMUSSEN, Poul, Baad [DK/DK]; Marstalsgade 23, DK-2100 København Ø (DK).

(74) Common Representative: NOVO NORDISK A/S; Thalsø-Madsen, Birgit, Corporate Patents, Novo Allé, DK-2880 Bagsvaerd (DK).

SG 9611634-8

(54) Title: HEPARIN-BINDING PROTEIN FOR THE TREATMENT OF SEPSIS AND PROCESSES FOR ITS PREPARATION

(57) Abstract

Pharmaceutical composition for the prevention or treatment of diseases or conditions associated with induction of the cytokine cascade by lipopolysaccharide (LPS), the composition comprising a heparin-binding protein (HBP) which, in glycosylated form, has an apparent molecular weight of 28 kD (as determined by SDS-PAGE under reducing conditions), the protein being produced in the azurophil granules of polymorphonuclear leukocytes, together with a pharmaceutically acceptable carrier or diluent. The heparin-binding protein is produced in host cells containing a DNA sequence encoding N-terminally extended HBP or encoding HBP preceded by and fused to a DNA sequence encoding another protein. Also disclosed is a process wherein the culture medium contains a sulphated polysaccharide.

8-[illegible]

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	**GB**	United Kingdom	**MR**	Mauritania
AU	Australia	**GE**	Georgia	**MW**	Malawi
BB	Barbados	**GN**	Guinea	**NE**	Niger
BE	Belgium	**GR**	Greece	**NL**	Netherlands
BF	Burkina Faso	**HU**	Hungary	**NO**	Norway
BG	Bulgaria	**IE**	Ireland	**NZ**	New Zealand
BJ	Benin	**IT**	Italy	**PL**	Poland
BR	Brazil	**JP**	Japan	**PT**	Portugal
BY	Belarus	**KE**	Kenya	**RO**	Romania
CA	Canada	**KG**	Kyrgystan	**RU**	Russian Federation
CF	Central African Republic	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CG	Congo			**SE**	Sweden
CH	Switzerland	**KR**	Republic of Korea	**SI**	Slovenia
CI	Côte d'Ivoire	**KZ**	Kazakhstan	**SK**	Slovakia
CM	Cameroon	**LI**	Liechtenstein	**SN**	Senegal
CN	China	**LK**	Sri Lanka	**TD**	Chad
CS	Czechoslovakia	**LU**	Luxembourg	**TG**	Togo
CZ	Czech Republic	**LV**	Latvia	**TJ**	Tajikistan
DE	Germany	**MC**	Monaco	**TT**	Trinidad and Tobago
DK	Denmark	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**US**	United States of America
FI	Finland	**ML**	Mali	**UZ**	Uzbekistan
FR	France	**MN**	Mongolia	**VN**	Viet Nam
GA	Gabon				

9611634-8